Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins

Toxicon

Volumn 53, Issue 6, 2009, Pages 616-624

  Kukreja, Roshan ^a   Chang, Tzuu Wang ^a   Cai, Shuowei ^a   Lindo, Paul ^a   Riding, Stephen ^a   Zhou, Yu ^a   Ravichandran, Easwaran ^a   Singh, Bal Ram ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

Botulinum neurotoxin; Botulinum neurotoxin complex; Botulism; Immunogenicity; Neurotoxin associated proteins

Indexed keywords

BOTULINUM TOXIN A; HEMAGGLUTININ; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BOTULISM; CLOSTRIDIUM BOTULINUM TYPE A; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL TRACT; GENE CLUSTER; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL PROTEINS; BOTULINUM TOXIN TYPE A; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN SUBUNITS; RABBITS;

CLOSTRIDIUM BOTULINUM;

EID: 62649097660     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.01.017     Document Type: Article

References (38)

1. Altschul S.F., Gish W., Miller W., Myers E.W., and Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 215 (1990) 403-410
2. Atassi Z.M. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 19 (2004) S68-S84
3. Benecke R., Jost W.H., Kanovsky P., Ruzicka E., Comes G., and Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64 (2005) 1949-1951
4. Besemer J., and Borodovsky M. Heristic approach to deriving models for gene finding. Nucleic Acids Res. 27 (1999) 3911-3920
5. Bhidayasiri R., and Truong D.D. Expanding use of botulinum toxin. J. Neurol. Sci. 235 (2005) 1-9
6. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 6 Suppl. (1997) S1-S23
7. Cai S., Sarkar H.K., and Singh B.R. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 38 (1999) 6903-6910
8. Chen F., Kuziemko G.M., and Stevens R.C. Biophysical characterization of the stability of the 150 kDa botulinum toxin, the nontoxic component, and the 900-kDa botulinum toxin complex species. Infect. Immun. 66 (1998) 2420-2425
9. Chen F., Kuziemko G.M., Amersdorfer P., Wong C., Marks J.D., and Stevens R.C. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect. Immun. 65 (1997) 1626-1630
10. DasGupta B.R., and Satyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 22 (1984) 415-424
11. Dressler D., and Saberi F.A. Botulinum toxin: mechanisms of action. Eur. Neurol. 53 (2005) 3-9
12. Fu F.N., Sharma S.K., and Singh B.R. A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum. J. Protein Chem. 17 (1998) 53-60
13. Fujinaga Y., Inoue K., Watanabe S., Yokota K., Hirai Y., Nagamachi E., and Oguma K. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology 143 (1997) 3841-3847
14. Gill S.C., and von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182 (1989) 319-326
15. Hasegawa K., Watanabe T., Suzuki T., Yamano A., Oikawa T., Sato Y., Kouguchi H., Yoneyama T., Niwa K., Ikeda T., and Ohyama T. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J. Biol. Chem. 282 (2007) 24777-24783
16. Inoue K., Fujinaga Y., Honke K., Yokota K., Ikeda T., Ohyama T., Takeshi T., Watanbe T., Inoue K., and Oguma K. Characterization of haemagglutinin activity of Clostridium botulinum type C and D 16S toxins, and one subcomponent of haemagglutinin (HA1). Microbiology 145 (1999) 2533-2542
17. Inoue K., Fujinaga Y., Watanabe T., Ohyama T., Takeshi K., Moriishi K., Nakajima H., Inoue K., and Oguma K. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. 64 (1996) 1589-1594
18. Jones R.G., Corbel M.J., and Sesardic D. A review of WHO International Standards for botulinum antitoxins. Biologicals 34 (2006) 223-226
19. Kelly G., Prasannan S., Daniell S., Fleming K., Frankel G., Dougan G., Connerton I., and Matthews S. Structure of cell-adhesion fragment of intimin from enteropathogenic Escherichia coli. Nat. Struct. Biol. 6 (1999) 313-318
20. Klien A.W. The therapeutic potential of botulinum toxin. Dermatol. Surg. 30 (2004) 452-455
21. Kukreja R., and Singh B.R. Comparative role of neurotoxin associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E. Biochemistry 46 (2007) 14316-14324
22. Lee J.C., Yokota K., Arimitsu H., Hwang H.J., Sakaguchi Y., Cui J., Takeshi K., Watanabe T., Ohyama T., and Oguma K. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151 (2005) 3739-3747
23. Li B., Qian X., Sarkar H.K., and Singh B.R. Molecular characterization of type E Clostridium botulinum and comparison to other types of Clostridium botulinum. Biochim. Biophys. Acta 1395 (1998) 21-27
24. Li L., and Singh B.R. High level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain. Protein Expr. Purif. 17 (1999) 339-344
25. Lindo, P., Chang, T.W., Zhou, Y., Singh, B.R., 2004. Identification of novel complexing protein of Clostridium botulinum neurotoxin complex. ASBMB Annual Meeting and 8th IUBMB Conference. B377, 9.
26. Lukashin A., and Borodovsky M. GeneMark.hmm: new solutions for gene finding. Nucleic Acids Res. 26 (1998) 1107-1115
27. Montecucco C., and Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 28 (1995) 423-472
28. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 19 (1983) 165-194
29. Sathyamoorthy V., and DasGupta B.R. Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E. J. Biol. Chem. 260 (1985) 10461-10466
30. Sharma S., and Singh B.R. Enhancement of the endopeptidase activity of purified neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 43 (2004) 4791-4798
31. Sharma S., and Singh B.R. Immunological protperties of Hn-33 purified from type A Clostridium botulinum. J. Nat. Toxins 9 (2000) 357-362
32. Sharma S.K., Ramzan M.A., and Singh B.R. Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 41 (2003) 321-331
33. Shukla H.D., and Sharma S.K. Clostridium botulinum: a bug with beauty and weapon. Crit. Rev. Microbiol. 31 (2005) 11-18
34. Singh B.R. Intimate details of the most poisonous poison. Nat. Struct. Biol. 7 (2000) 617-619
35. Singh B.R., and DasGupta B.R. Changes in the molecular topography of the light and heavy chains of botulinum neurotoxin following their separation. Biophys. Chem. 34 (1989) 259-267
36. Wenzel R.G. Pharmacology of botulinum neurotoxin serotype A. Am. J. Health Syst. Pharm. 61 (2004) S5-S10
37. Yang, W., Lindo, P., Riding, S., Chang, T.W., Cai, S., Van, T., Kukreja, R., Zhou, Y., Vasa, K., Singh, B.R. Expression, purification and comparative characterization of enzymatically deactivated recombinant botulinum neurotoxin type A. Botulinum J., in press.
38. Zhou Y., Paturi S., Lindo P., Sheosmith S.M., and Singh B.R. Cloning, expression, purification, and characterization of biologically active recombinant hemagglutinin-33, type A botulinum neurotoxin associated protein. Protein J. 26 (2007) 29-37